AP News, November 10, 2025: AP explains FDA decision to
delete most black box warnings for hormone therapy for menopause,
despite controversies about the risks. NCHR’s Diana Zuckerman
says FDA lost credibility for deleting such important warnings without
scientific review using FDA Advisory Committee.
News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
F.D.A. Will Remove Black Box Warnings From Hormone Treatments for Menopause
The New York Times, November 10, 2025: This NYT article describes the different data and opinions regarding FDA Commissioner Makary’s decision to remove the black box from all hormone therapy products for menopause despite risks of cancer and stroke. NCHR president Dr. Diana Zuckerman explains why this is a step backward for women’s health.
Read More »FDA ‘serious’ about hormone therapy changes
Politico, October 28, 2025: Politico predicts FDA will revise black box warnings on hormones for menopause, but it isn’t clear how. NCHR’s Diana Zuckerman explains warnings are needed but require more nuance because the evidence is different for hormone creams compared to pills, and evidence of risks and benefits for pills depend on factors such as the type of hormones and the age, medical history, and other differences in the women.
Read More »Some MAHA Supporters Say CNPV Could Lower FDA Standards
Inside Health Policy, October 23, 2025: Inside Health Policy quotes a MAHA meeting that criticized industry influence over FDA, the impact of user fees, the inappropriate reliance on surrogate endpoints for cancer screening and Alzheimer’s drugs. The Lever FDA report finding that most new drugs are approved on evidence inferior to the FDA’s legal standards. NCHR’s Diana Zuckerman is quoted criticizing the FDA’s new CNVP program that promises extremely fast priority reviews for high-impact drugs.
Read More »Kennedy’s Ties to Ally Leading Vaccine Lawsuits Raise Ethical Concerns
New York Times, Oct. 3, 2025: This NYT investigation shows how RFK Jr’s lawyer and long-time colleague Aaron Siri benefits financially from his influence over RFK and HHS, resulting in vaccine policies and other decisions that harm U.S. patients. NCHR president Diana Zuckerman’s experience is included as an example.
Read More »